OBJECTIVE: Convection-enhanced delivery using carboplatin in brainstem glioma models was reported to prolong survival. Functional impairment is of additional importance to evaluate the value of local chemotherapy. We established a neurological scoring system for the rat brainstem glioma model. MATERIAL AND METHODS: In 46 male Fisher rats stereotactically 10(5) F-98 cells were implanted at 1.4-mm lateral to midline and at the lambdoid suture using guided screws. Following 4 days local delivery was performed using Alzet pumps (1 microl/h over 7 days) with either vehicle (5% dextrose) or carboplatin via one or two cannulas, respectively. All rats were subsequently tested neurologically using a specified neurological score. In 38 animals survival time was recorded. Representative MR imaging were acquired in eight rats, respectively, at day 12 after implantation. HE staining was used to evaluate tumor extension. RESULTS: Neurological scoring showed significantly higher impairment in the high dose carboplatin group during the treatment period. Survival was significantly prolonged compared to control animals in the high dose carboplatin-one cannula group as well as in both low dose carboplatin groups (18.6 +/- 3 versus 26.3 +/- 9, 22.8 +/- 2, 23.6 +/- 2 days; p < 0.05). Overall neurological grading correlated with survival time. MR imaging showed a focal contrast enhancing mass in the pontine brainstem, which was less exaggerated after local chemotherapy. Histological slices visualized decreased cellular density in treatment animals versus controls. CONCLUSION: Local chemotherapy in the brainstem glioma model showed significant efficacy for histological changes and survival. Our neurological grading enables quantification of drug and tumor-related morbidity as an important factor for functional performance during therapy.
OBJECTIVE: Convection-enhanced delivery using carboplatin in brainstem glioma models was reported to prolong survival. Functional impairment is of additional importance to evaluate the value of local chemotherapy. We established a neurological scoring system for the rat brainstem glioma model. MATERIAL AND METHODS: In 46 male Fisher rats stereotactically 10(5) F-98 cells were implanted at 1.4-mm lateral to midline and at the lambdoid suture using guided screws. Following 4 days local delivery was performed using Alzet pumps (1 microl/h over 7 days) with either vehicle (5% dextrose) or carboplatin via one or two cannulas, respectively. All rats were subsequently tested neurologically using a specified neurological score. In 38 animals survival time was recorded. Representative MR imaging were acquired in eight rats, respectively, at day 12 after implantation. HE staining was used to evaluate tumor extension. RESULTS: Neurological scoring showed significantly higher impairment in the high dose carboplatin group during the treatment period. Survival was significantly prolonged compared to control animals in the high dose carboplatin-one cannula group as well as in both low dose carboplatin groups (18.6 +/- 3 versus 26.3 +/- 9, 22.8 +/- 2, 23.6 +/- 2 days; p < 0.05). Overall neurological grading correlated with survival time. MR imaging showed a focal contrast enhancing mass in the pontine brainstem, which was less exaggerated after local chemotherapy. Histological slices visualized decreased cellular density in treatment animals versus controls. CONCLUSION: Local chemotherapy in the brainstem glioma model showed significant efficacy for histological changes and survival. Our neurological grading enables quantification of drug and tumor-related morbidity as an important factor for functional performance during therapy.
Authors: G Pöpperl; R Goldbrunner; F J Gildehaus; F W Kreth; P Tanner; M Holtmannspötter; J C Tonn; K Tatsch Journal: Eur J Nucl Med Mol Imaging Date: 2005-05-05 Impact factor: 9.236
Authors: C R Freeman; J P Krischer; R A Sanford; M E Cohen; P C Burger; R del Carpio; E C Halperin; L Munoz; H S Friedman; L E Kun Journal: Int J Radiat Oncol Biol Phys Date: 1993-09-30 Impact factor: 7.038
Authors: O A Fernández-Hidalgo; V Vanaclocha; J M Vieitez; J J Aristu; J Rebollo; A Gúrpide; J M Aramendía; R Moreno-Palanques; S Martín-Algarra; M L Subirá; A Brugarolas Journal: Bone Marrow Transplant Date: 1996-07 Impact factor: 5.483
Authors: R J Strege; Y J Liu; A Kiely; R M Johnson; E M Gillis; P Storm; B S Carson; G I Jallo; M Guarnieri Journal: J Neurooncol Date: 2004-05 Impact factor: 4.130
Authors: Jung Hwan Kim; Garrett W Astary; Tatiana L Nobrega; Svetlana Kantorovich; Paul R Carney; Thomas H Mareci; Malisa Sarntinoranont Journal: J Neurosci Methods Date: 2012-06-08 Impact factor: 2.390
Authors: Richard C E Anderson; Benjamin Kennedy; Candix L Yanes; James Garvin; Michael Needle; Peter Canoll; Neil A Feldstein; Jeffrey N Bruce Journal: J Neurosurg Pediatr Date: 2012-12-14 Impact factor: 2.375
Authors: Weilian Yang; Rolf F Barth; Gong Wu; Tianyao Huo; Werner Tjarks; Michael Ciesielski; Robert A Fenstermaker; Brain D Ross; Carol J Wikstrand; Kent J Riley; Peter J Binns Journal: J Neurooncol Date: 2009-07-09 Impact factor: 4.130
Authors: Quintino Giorgio D'Alessandris; Simone Pacioni; Vittorio Stumpo; Mariachiara Buccarelli; Liverana Lauretti; Martina Giordano; Rina Di Bonaventura; Maurizio Martini; Luigi M Larocca; Stefano Giannetti; Nicola Montano; Maria Laura Falchetti; Lucia Ricci-Vitiani; Roberto Pallini Journal: Biomed Res Int Date: 2021-03-08 Impact factor: 3.411